Перегляд за Автор "Boiko, Dmytro I."

Зараз показуємо 1 - 4 з 4
  • Ескіз недоступний
    Документ
    Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor/neuropsychiatric subtypes
    (Elsevier, 2022-06) Shkodina, Anastasiia D.; Tarianyk, Kateryna A.; Boiko, Dmytro I.; Zehravi, Mehrukh; Akter, Shamima; Ashraf, Ghulam Md.; Rahman, Md. Habibur; Шкодіна, Анастасія Дмитрівна; Таряник, Катерина Анатоліївна; Бойко, Дмитро Іванович
    Parkinson’s disease (PD) is a neurological disorder, related to rigidity, bradykinesia, and resting tremors, among other motor symptoms. It is noticed in the increasing frequency of neuropsychiatric disorders, which may be also caused by non-motor symptoms of PD. Treatment of PD is usually based on the classification of motor subtypes; however, it remains unclear whether motor subtypes have differences in the severity of psychiatric symptoms. It determines the importance of discovering possible neuropsychiatric subtypes of PD. We conducted a clinical study, which included group 1 - patients with postural instability and gait disorders dominant (PIGD) subtype, group 2 - patients with tremor dominant (TD) and indeterminate subtypes (non-PIGD), and group 3 - people who did not have CNS damage. We used the Montreal Cognitive Assessment, Russified 20-point version of the Toronto Alexithymia Scale, State-Trait Anxiety Inventory, and Beck Depression Inventory for assessment of the mental status. It was the first time that neuropsychiatric subtypes of PD had been investigated based on the condition of cognition and mood. Cluster analysis gave us the possibility to classify our patients by the following subtype: affective-cognitive PIGD, anxious PIGD, affective-cognitive non-PIGD, and non-PIGD without psychiatric symptoms. This indicates a closed link between psychiatric and motor symptoms, which can be used for the improved treatment of PD.
  • Ескіз недоступний
    Документ
    Drug reprofiling history and potential therapies against Parkinson’s disease
    (2022-10-26) Latif, Komal; Ullah, Aman; Shkodina, Anastasiia D.; Boiko, Dmytro I.; Rafique, Zakia; Alghamdi, Badrah S.; Alfaleh, Mohamed A.; Ashraf, Ghulam Md.; Шкодіна, Анастасія Дмитрівна; Бойко, Дмитро Іванович
    Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing “old” drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the way toward utilizing existing medications in treating diseases other than the purposes they were initially designed for. Faced with scientific and economic challenges, the prospect of discovering new medication indications is enticing to the pharmaceutical sector. Medication repurposing can be used at various stages of drug development, although it has shown to be most promising when the drug has previously been tested for safety. We describe strategies of drug repurposing for Parkinson’s disease, which is a neurodegenerative condition that primarily affects dopaminergic neurons in the substantia nigra. We also discuss the obstacles faced by the repurposing community and suggest new approaches to solve these challenges so that medicine repurposing can reach its full potential.
  • Ескіз недоступний
    Документ
    Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression
    (Springer, 2022-06) Boiko, Dmytro I.; Shkodina, Anastasiia D.; Hasan, Mohammad Mehedi; Bardhan, Mainak; Kazmi, Syeda Kanza; Chopra, Hitesh; Bhutra, Prerna; Baig, Atif Amin; Skrypnikov, Andrii M.; Бойко, Дмитро Іванович; Шкодіна, Анастасія Дмитрівна; Скрипніков, Андрій Миколайович
    A complex pathogenesis involving several physiological systems is theorized to underline the development of depressive disorders. Depression is accompanied by circadian regulation disruption and interaction with the functioning of both central and peripheral oscillators. Many aspects of melatonin function unite these systems. The use of drugs for circadian rhythm disorders could inspire a potential treatment strategy for depression. Melatonin plays an essential role in the regulation of circadian rhythms. It exerts effect by activating two types of melatonin receptors, type 1A (MT1) and 1B (MT2). These are G-protein-coupled receptors, predominantly located in the central nervous system. MT1/MT2 agonists could be a useful treatment approach according to all three prevalent theories of the pathogenesis of depression involving either monoamines, synaptic remodeling, or immune/inflammatory events. MT1/MT2 receptors can be a potential target for novel antidepressants with impact on concentrations of neurotrophins or neurotransmitters, and reducing levels of pro-inflammatory cytokines. There is an interesting cross-talk mediated via the physical association of melatonin and serotonin receptors into functional heteromers. The antidepressive and neurogenetic effects of MT1/MT2 agonists can also be caused by the inhibition of the acid sphingomyelinase, leading to reduced ceramide, or increasing monoamine oxidase A levels in the hippocampus. Compounds targeting MT1 and MT2 receptors could have potential for new anti-depressants that may improve the quality of therapeutic interventions in treating depression and relieving symptoms. In particular, a combined effect on MT1 and/or MT2 receptors and neurotransmitter systems may be useful, since the normalization of the circadian rhythm through the melatonergic system will probably contribute to improved treatment. In this review, we discuss melatonergic receptors as a potential additional target for novel drugs for depression.
  • Ескіз недоступний
    Документ
    Relationship between Sleep Disorders and Neuropsychiatric Symptoms in Parkinson's Disease: A Narrative Review
    (2022-10) Shkodina, Anastasiia D.; Iengalychev, Tymur R.; Tarianyk, Kateryna A.; Boiko, Dmytro I.; Lytvynenko, Nataliia V.; Skrypnikov, Andrii M.; Шкодіна, Анастасія Дмитрівна; Таряник, Катерина Анатоліївна; Бойко, Дмитро Іванович; Литвиненко, Наталія Володимирівна; Скрипніков, Андрій Миколайович
    Aim: The objective of this narrative review was to describe the versatile links between mental status and sleep in patients with Parkinson's disease. Methods: We searched randomized controlled studies, observational studies, meta-analyses, systematic reviews, and case reports written in English in PubMed during 2015 - 2021. Additionally, to ensure the completeness of the review, a second, more in-depth literature search was performed using the same electronic database with the search inquiries of increased specificity. Results: The information on pathophysiology, epidemiology, clinical features and risk factors was extracted and formed the basis for this review. Despite how widespread sleep disorders in Parkinson’s disease are, there is no systematic information about their association with neuropsychiatric symptoms, such as depression, anxiety, impulse control disorders, apathy, cognitive impairment and psychosis. In this review, we described relationships between these non-motor symptoms of Parkinson’s disease, their timeline occurrence, gap in knowledge and perspectives for further research. We suppose that early treatment of sleep disorders in patients with Parkinson’s disease can reduce the incidence and extent of neuropsychiatric symptoms. Conclusion: We have demonstrated multiple, multidirectional relationships between sleep disorders and neuropsychiatric symptoms. However, some of them remain unexplored. The described knowledge can be applied to further study the possibility of influencing neuropsychiatric symptoms through the correction of sleep disorders in patients with different stages of Parkinson’s disease.